Exopharm Ltd
ASX:EX1

Watchlist Manager
Exopharm Ltd Logo
Exopharm Ltd
ASX:EX1
Watchlist
Price: 0.023 AUD Market Closed
Market Cap: 1.6m AUD

Operating Margin

-345.2%
Current
Declining
by 129.6%
vs 3-y average of -215.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-345.2%
=
Operating Income
AU$-4.2m
/
Revenue
AU$1.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-345.2%
=
Operating Income
AU$-4.2m
/
Revenue
AU$1.2m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Exopharm Ltd
ASX:EX1
1.6m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in Australia
Percentile
34rd
Based on 3 951 companies
34rd percentile
-345.2%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Exopharm Ltd
Glance View

Market Cap
1.6m AUD
Industry
Biotechnology

Exopharm Ltd. engages in the development and commercialization of exosomes as therapeutic agents. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-12-18. The firm is focused on developing and commercializing exosomes as therapeutic agents. The firm has three technologies that allows customization of exosomes, in which the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Its LEAP manufacturing technology provides access to exosomes for research and clinical uses. The firm is developing Engineered EVs (EEVs), are an emerging form of precision medicine with application in areas, such as neurology, cardiology and oncology. Its EEV projects under development are Fortrexo, Cognevo and PlexoDOX.

EX1 Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-345.2%
=
Operating Income
AU$-4.2m
/
Revenue
AU$1.2m
What is Exopharm Ltd's current Operating Margin?

The current Operating Margin for Exopharm Ltd is -345.2%, which is below its 3-year median of -215.6%.

How has Operating Margin changed over time?

Over the last 3 years, Exopharm Ltd’s Operating Margin has decreased from -278.5% to -345.2%. During this period, it reached a low of -345.2% on Jan 31, 2024 and a high of -102.2% on Dec 31, 2022.

Back to Top